Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6 : a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

DSpace Repository

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6 : a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

Author: Salwender, Hans; Bertsch, Uta; Weisel, Katja; Duerig, Jan; Kunz, Christina; Benner, Axel; Blau, Igor W.; Raab, Marc Steffen; Hillengass, Jens; Hose, Dirk; Huhn, Stefanie; Hundemer, Michael; Andrulis, Mindaugas; Jauch, Anna; Seidel-Glaetzer, Andrea; Lindemann, Hans-Walter; Hensel, Manfred; Fronhoffs, Stefan; Martens, Uwe; Hansen, Timon; Wattad, Mohammed; Graeven, Ullrich; Munder, Markus; Fenk, Roland; Haenel, Mathias; Scheid, Christof; Goldschmidt, Hartmut
Tübinger Autor(en):
Weisel, Katja
Published in: Bmc Cancer (2019), Bd. 19, Article 504
Verlagsangabe: Bmc
Language: English
Full text: http://dx.doi.org/10.1186/s12885-019-5600-x
ISSN: 1471-2407
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)